Additionally, the FDA has documented instances of patients self-administering incorrect doses due to confusion over measurement and dosing instructions
Mehri, R., Alatrash, A., Ogrodnik, N., Lee Slew, K., & Matida, E
Following dichotomization of ALT responders based on a median 12.9% decrease from baseline, we found that ALT responders were younger in age and did not have severe diabetes compared with ALT non-responders
Pujadas G, Drucker DJ
Stratifying by the presence or absence of endogenous C-peptide as a potential protective factor against DKA should also be investigated
The medication is available under different brand names: Ozempic (approved for diabetes) and Wegovy (specifically approved for weight loss)